To the Editor: In their randomized trial, Dr Galløe and colleagues1 compared the efficacy and safety of sirolimus-eluting and paclitaxel-eluting stents in a study design reflecting common clinical practice. In the trial design,2 the authors defined the primary outcome measures as “MACE (cardiac death, MI, TVR, TLR, TVF) during 9 months.” However, in the article's power calculation, the authors used estimated 5-year event rates for sample size calculation: “The SORT OUT II trial was therefore planned to enroll at least 1800 patients to detect a minimum relevant relative difference in rates of 25% (ie, rates of 20% vs 15%) with 5 years of follow-up.”